Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12042008 | 0.99 | NR1H4 (0.45) | NR1H4PTGER3PTGER2ACACBHSD11B1 | |
| Lithium Ion SCHEMBL454687 | 0.86 | HSD11B1 (0.41) | NR1H4ACACBHSD11B1HTR7LMNA | |
| SCHEMBL381875 | 0.82 | HTR1A (0.50) | NR1H4HTR7ITGB3ITGA2BLMNA | |
| SCHEMBL12041659 | 0.81 | HTR1A (0.51) | NR1H4HTR7ITGB3ITGA2BLMNA | |
| SCHEMBL381362 | 0.75 | ALDH1A1 (0.51) | PTGER3PTGER2HTR7LMNAMAPT | |
| SCHEMBL454689 | 0.74 | NR1H4 (0.40) | NR1H4PTGER3PTGER2ACACBLMNA | |
| SCHEMBL462264 | 0.74 | HRH3 (0.50) | NR1H4PTGER3PTGER2HSD11B1LMNA | |
| SCHEMBL12041897 | 0.73 | ALDH1A1 (0.52) | PTGER3PTGER2HTR7LMNAMAPT | |
| SCHEMBL12042054 | 0.72 | HRH3 (0.51) | NR1H4PTGER3PTGER2HSD11B1LMNA | |
| SCHEMBL463204 | 0.71 | PTGER2 (0.53) | NR1H4PTGER3PTGER2HSD11B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| EP-2408742-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-09-03 | — | — | EP | disclosed |
| EP-2408742-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2012-01-25 | — | — | EP | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| WO-2010115688-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | NR1H4 1493/4885PTGER3 1933/4885PTGER2 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.